ARTICLE | Clinical News
IPH4102 regulatory update
September 15, 2014 7:00 AM UTC
The European Commission granted Orphan Drug designation to IPH4102 to treat cutaneous T cell lymphoma (CTCL). Next year, Innate plans to begin a Phase I trial with the humanized mAb against killer ce...